Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.445
Bid: 2.40
Ask: 2.60
Change: 0.00 (0.00%)
Spread: 0.20 (8.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.445
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: RA International loss narrows as revenue grows

Thu, 07th Sep 2023 17:07

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Pantheon Resources PLC - London-based oil and gas company focused on onshore operations in the US - Agrees a private placement of 11.9 million shares at a price of GBP0.1878 each for a total USD2.8 million to IPGL Ltd, a long-term shareholder. Pantheon will use the funds to pay the full quarterly bond repayment of the same amount. Therefore, the placement is cash-neutral and should result in materially similar dilution than would have been the case had the company settled the bond repayment in shares.

----------

Immupharma PLC - London-based drug discovery and development company - Further to announcement on August 31, raises GBP130,683 via the issue of around 6.5 million shares at 2 pence each to existing retail investors, in addition to the GBP1.4 million raised in the subscription and direct subscription. Notes Lisa Baderoon, director, subscribed for 1.0 million retail offer shares.

----------

Technology Minerals PLC - London-based battery metals mining and recycling firm - Raises GBP700,000 from a long-term shareholder through the issue of convertible loan notes. The convertible loan notes carry a coupon of 12% for a term of twelve months from issue and are convertible into shares at 1.4 pence each. "The funding will support the company as it continues to advance its exploration assets up the value curve and Recyclus progresses through the commissioning phase at its Li-ion battery recycling plant and moves closer to commercial production," says Alex Stanbury chief executive.

----------

Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Announces further progress from Hikma in the development of ready-to-use injectable medicine AT307, following a recent positive pre-investigational new drug application meeting between Hikma and the US Food & Drug Administration. In January, Arecor transferred all rights and responsibility for future development and commercialisation of AT307 to Hikma as part of an earlier co-development and license agreement. Under this pact, Arecor is eligible to receive development milestone payments in addition to future recurring revenue from royalty payments upon commercialisation. Hikma has communicated to Arecor its intention to continue the development of AT307 in the US using the FDA's 505(b)(2) regulatory pathway. This pathway provides companies with an abbreviated regulatory review process when evidence of safety and clinical efficacy generated for an originator product is deemed suitable to be relied upon in new marketing applications.

----------

Egdon Resources PLC - Reading-based oil and gas explorer and producer - Further to the announcement of August 7, says Egdon, York Energy (UK) Holdings Ltd and Cuadrilla North Cleveland Ltd have executed a fully termed agreement to enable a farm-in and equalisation of interests between the PL81 and PEDL347 licences. Licences will be assigned as follows: Egdon 52.5%, Cuadrilla 25% and York 22.5%. Egdon would be appointed as the operator of the licences. As consideration, Egdon will pay 100% of the costs associated with the planning, drilling, logging, and either short term testing and completion or plugging and abandonment of a well to optimally test the Weaverthorpe prospect.

----------

Canadian General Investments Ltd - closed-end equity fund focused on Canadian firms - Reports net asset value per share at August 31 was USD57.57, resulting in year-to-date and 12-month NAV returns, with dividends reinvested, of 20.9% and 21.6%, respectively. No comparative NAV figure was given.

----------

RA International Group PLC - specialist provider of complex and integrated remote site services - Says in the six months to June 30 revenue rose 4.1% to USD30.4 million from USD29.2 million the year prior. Pretax loss narrowed to USD2.5 million from USD3.4 million with loss per share of 1.4 pence compared to 2.0p the year before. Highlights order book of USD 71 million at June 30, although this was down from USD96 million last year.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
28 Jan 2013 16:06

ImmuPharma non-exec reduces stake

Dr Ajay Agrawal, Non-Executive Director of ImmuPharma, sold a stack of shares in the AIM-listed drug company, it was announced Monday. Agrawal traded in 62,169 shares at 57p a time on January 24th, pocketing £35,436 before tax. The deal was announced the same day the group said its key scientific

Read more
28 Jan 2013 12:58

Immupharma reports success of partner's latest Lupus drug trial

Drug development firm ImmuPharma said Monday that its key scientific collaboration partner and the inventor of ImmuPharma's lead compound, Lupuzor, has confirmed the effectiveness of a product known as Lupuzor peptide P140. Partner CNRS released a statement saying that in a clinical trial involvin

Read more
27 Mar 2012 10:27

ImmuPharma's losses grow in 2011

Drug development firm ImmuPharma increased its losses during 2011 but managed to regain the rights to its most important compound. The loss for the year was £3.35m, against the prior year's loss of £1.98m. The loss per share increased from 2.44p in 2010 to 4.12p in 2011. ImmuPharma's lead product

Read more
24 Jan 2012 16:32

SABMiller exec buys a round

The Managing Director of SABMiller's African division bought a round of shares just one day before the drinks giant announced it has signed a definitive transaction agreement with Anadolu Group and Anadolu Efes. The agreement allows the firm to form a strategic alliance between the firm's divisions

Read more
5 Apr 2011 12:01

Immupharma posts wider losses

Drug discovery group Immupharma fell into losses in the year to 31 December, but pointed to progress with its ongoing trials. Pre-tax losses totalled £2m for the year, against a profit of £9.1m the previous year. Revenues fell to just £325,000 from £22.05m. "Early results of our cancer programme

Read more
23 Jun 2010 16:00

UK SMALLCAP ROUNDUP: Mariana Resources Raises GB6.75 Million

Dow Jones smallcap news is on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps MARIANA RESOURCES LTD. (MARL.LN), a gold, silver and copper explorer, Wednesday said it agreed to raise GBP6.75 million in a share sale to fund drilling at i

Read more
23 Jun 2010 07:28

Immupharma Partner Cephalon Starts Phase 2b Trials Recruitment

LONDON (Dow Jones)--Immupharma PLC (IMM.LN), a specialist drug discovery and development company, said Wednesday that Cephalon Inc. (CEPH), its license partner for IPP-201101 (Rigerimod; Lupuzor) has started the recruitment of lupus patients for a Phase IIb trial in the U.S. MAIN FACTS: -Stu

Read more
19 Nov 2009 11:01

Small caps round-up: White Young Green, Beowulf, Angel Biotech...

Engineering consultant White Young Green has traded in line with expectations since the end of June, with conditions varying across its markets. "There remains a lack of confidence and liquidity in many areas in which we trade, but there are also some encouraging signs in respect of opportunities

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.